Chairman of the Board
Gunnar Mattsson is Partner of Advokatfirman Lindahl, one of Sweden’s largest law firms, since 1994. Head of Lindahl’s life sciences practice 2009-2014. He is internationally ranked as a leading lawyer within life sciences and has extensive experience as Director of public and private companies within pharmaceuticals and biotechnology.
David Berglund, M.D., Ph.D., M.B.A., is an Associate Professor of Immunology at Uppsala University that has published more than 40 peer-reviewed articles in areas ranging from transplant immunology and oncology to transfusion medicine and biomaterials. David also received clinical training in transplant and reconstructive plastic surgery at Uppsala University Hospital and Karolinska University Hospital in Sweden. He has worked with drug development for more than ten years focusing on strategic leadership questions of both early- and late-stage pharmaceutical companies. David holds an M.B.A. from NYU Stern School of Business with specializations in Corporate Finance and Leadership & Change Management.
Lena Degling Wikingsson
Lena Degling Wikingsson is a pharmacist by training and holds a PhD in Pharmaceutical Science. She has over 20 years of experience in the pharmaceutical industry and has previously been CEO of Independent Pharmaceutica AB and Avaris AB, a non-executive Director of Avaris AB, held positions at SBL Vaccines, Accuro Immunology, and worked as a biotechnology assessor at the Swedish Medical Products Agency. She has broad experience in regulatory affairs and the development of biologics and vaccines. Lena Degling Wikingsson is currently a non-executive Director of Simplexia and CEO of Dilafor AB.
Agneta Edberg has over 25 years’ experience from leading positions in the life sciences industry. She has been CEO at Mylan AB and the Swedish Pharmaceutical Insurance and has held leading positions within Pfizer, Bactiguard and Cilag (Johnson & Johnson). Agneta Edberg has been chairman of the board of Immunicum AB, an immuno-oncology company listed on the Stockholm Stock Exchange. She is also chairman of the board of Idogen AB and participates on the board of the Vinnova project CAMP, Centre for Advanced Medical Products. Since 2020, she participates on the board of the Vinnova Competence Center NextGenNK, focusing on the development of next-generation NK cell-based immunotherapies.
Ted Fjällman is Partner at Flerie Invest, a European biotech and pharma investor managing a portfolio of more than 20 companies in the US, UK, Sweden and other countries. Ted has been CEO and board member of several biotech companies engaged in a wide range of areas including immunology, oncology and biologics development and manufacturing. He holds a Ph.D. in Biotechnology and Immunology from the University of Guelph, Canada and splits his time between the UK, Sweden and Switzerland.
Hans-Gustaf Ljunggren (MD, PhD) serves as a Professor at Karolinska Institutet and is the Founder of the Centre for Infectious Medicine (CIM) and former Dean of Research at Karolinska Institutet. He has a long background in NK cell-related research, including NK cell-based cancer immunotherapy. Since 2020, he is the Director of the Vinnova Competence Center NextGenNK, focusing on the development of next-generation NK cell-based immunotherapies. He serves on several boards and SABs in the area of cancer immunotherapy. He is a member of the Nobel Assembly of Karolinska Institutet.
Stephen Wooding, MB;BS, BSc,FFPM, MBA, has made a long career in taking innovative science through the drug development process to benefit patients. He has spent nearly three decades at Johnson & Johnson’s pharmaceutical division Janssen. He started within R&D and finally took up a leadership role at the commercial/R&D interface as a member of Janssen’s global senior leadership team. He qualified in medicine at St Bartholomew’s Hospital, London, UK, and after six years in the NHS joined the pharmaceutical industry, initially in R&D, then broadening his experience to take on commercial roles and ultimately help shape a market access function. Stephen is currently Principal at Edipol Pharmaceutical Consulting Ltd, including supporting two start-ups as Chief Scientific Officer.